IHL-42X: Obstructive sleep apnea
IHL-42X is an oral fixed-dose of acetazolamide & dronabinol currently in clinical studies for the treatment of obstructive sleep apnea (OSA).
incannex.comCrawled Nov 15, 2026
IHL-42X is an oral fixed-dose of acetazolamide & dronabinol currently in clinical studies for the treatment of obstructive sleep apnea (OSA).
IHL-675A is an oral fixed-dose of cannabidiol and hydroxychloroquine sulfate being studied for the treatment of rheumatoid arthritis (RA).
Incannex’s pipeline includes combination therapies for obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.
PSX-001 is an oral synthetic psilocybin currently being studied in combination with psychological support as a treatment for adults with Generalized Anxiety Disorder (GAD).
Incannex runs clinical trials for obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.
Incannex develops therapies for chronic conditions and introduces its leadership team.
Incannex accepts partnership, investor, media, and general inquiries.
The company partners to address unmet medical needs in healthcare and advance new treatments.
Meet Incannex Healthcare Inc — a science-led pharmaceutical company innovating novel oral treatments, starting with obstructive sleep apnea.
This Cookie Notice explains how Incannex uses cookies and similar technologies on this website.
Incannex Healthcare doses the first patient in its **DReAMzz Phase 2 trial** of **IHL-42X**, a combination therapy for **obstructive sleep apnea**. The company also secures a **U.S. composition patent** for IHL-42X and reports a **$70 million cash position**. These updates highlight progress in clinical development and intellectual property for its sleep disorder treatment pipeline.
Incannex Healthcare Inc. begins dosing patients in the **DReAMzz Phase 2 trial** of **IHL-42X**, its oral fixed-dose combination therapy for **obstructive sleep apnea (OSA)**. The study aims to optimize dosing for the drug candidate, marking a key milestone in clinical development. Incannex specializes in combination therapies for high-impact medical conditions.
Incannex Healthcare secures a **A$5.1 million** R&D tax incentive refund from Australia’s government program, completing over **A$11.2 million** in non-dilutive capital for 2026. The refund follows approval of the company’s overseas research findings and adjustments to its FY25 tax filings. Incannex develops psychedelic-assisted therapies and combination treatments in clinical-stage trials.
Incannex Healthcare Inc. begins screening participants for its **DReAMzz Phase 2 study**, testing **IHL-42X** as a treatment for **obstructive sleep apnea (OSA)**. The dose confirmation trial evaluates the drug’s efficacy in this high-impact indication. IHL-42X previously received **Fast Track designation** from regulatory authorities.
Incannex Healthcare Inc. receives a U.S. patent for its treatment composition IHL-42X targeting obstructive sleep apnea. The patent covers compositions and methods for addressing the condition, marking a key milestone in the company’s clinical-stage pipeline. Incannex specializes in combination therapies for high-impact medical indications.
Incannex Healthcare supports the White House Executive Order accelerating psychedelic treatments for serious mental illness. The company’s PSX-001 program, a clinical-stage combination therapy, aligns with the initiative’s goals. Incannex develops innovative therapies targeting unmet needs in mental health care.

Incannex, a clinical-stage biopharmaceutical company, develops combination therapeutics targeting biological pathways behind chronic conditions.